Last reviewed · How we verify
NCT04022681
Long-term Follow Up of Patients in the Birmingham and Lambeth Liver Evaluation Strategies (BALLETS) Study
trial testing BALLETS in Fatty Liver in 1,237 participants. Completed in 1 July 2013.
1 May 2010
Quick facts
| Lead sponsor | University of Warwick |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,237 |
| Start date | 1 December 2005 |
| Primary completion | 1 May 2010 |
| Estimated completion | 1 July 2013 |
Drugs / interventions tested
- BALLETS
Conditions studied
- Fatty Liver — all drugs for Fatty Liver →
- Liver Diseases — all drugs for Liver Diseases →
Sponsor
University of Warwick
Who can join
Adults 18 to 100, any sex, with Fatty Liver or Liver Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will follow-up a cohort of patients from the Birmingham and Lambeth Liver Evaluation Strategies (BALLETS) study using a database search based on their individual National Health Service (NHS) numbers. The investigators will interrogate the Hospital Episode Statistics database and the Office of National Statistics database, and examine three categories of end points: death, inpatient attendance primarily due to liver disease, and outpatient attendance primarily due to liver disease. A logistic regression analysis will then be conducted to determine associations between these end points and the presence, and degree, of fatty liver in the original BALLETS study, adjusted for age, sex, alcohol intake, BMI, and baseline ALT measurement.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04022681
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fatty Liver
Currently open trials in the same condition.
- NCT07242222 — Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT07238985 — Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT06989723 — Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes · Phase 4 · recruiting
- NCT06203548 — Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter · NA · recruiting
Other University of Warwick trials
Trials by the same sponsor.
- NCT06334718 — Drone Delivered Defibrillators (The 3D Project). · completed
- NCT05402436 — Breast Screening Atypia and Subsequent Development of Cancer in England · completed
- NCT04977414 — Making Data Count Intervention Evaluation · NA · completed
- NCT05046197 — Evaluating the Integration of the Recommended Summary Plan for Emergency Care Treatment (ReSPECT) Into Primary Care · completed
- NCT05247463 — English Mammography Screening Outcomes by Age, Frequency and Test Threshold · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04022681 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Warwick
- Last refreshed: 17 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04022681.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing